Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 14/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL664542 | 0.90 | ALOX15 (0.48) | CTSANPC1RAB9AADRB2MEN1 | |
| SCHEMBL667453 | 0.88 | CTSA (0.48) | CTSANPC1RAB9AADRB2MEN1 | |
| SCHEMBL662588 | 0.83 | CTSA (0.40) | CTSANPC1RAB9A | |
| SCHEMBL662300 | 0.81 | CYP1A2 (0.41) | CTSAKMT2A | |
| SCHEMBL667099 | 0.78 | CTSA (0.46) | CTSANPC1RAB9AKMT2A | |
| SCHEMBL666275 | 0.78 | HDAC3 (0.38) | CTSANPC1RAB9A | |
| SCHEMBL30497676 | 0.77 | NPC1 (0.46) | CTSANPC1RAB9AMEN1KMT2A | |
| SCHEMBL306964 | 0.74 | CA1 (0.54) | KMT2A | |
| SCHEMBL29386813 | 0.74 | CA1 (0.54) | KMT2A | |
| SCHEMBL4504292 | 0.73 | IDO1 (0.51) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2018-05-17 | — | — | US | disclosed |
| US-20130165427-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130059869-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | HYDRA BIOSCIENCES, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20120108614-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC. | 2012-05-03 | — | — | US | disclosed |
| US-8163761-B2 | Methods and compositions for treating disorders | HYDRA BIOSCIENCES, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120046305-A1 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS | ELI LILLY AND COMPANY | 2012-02-23 | — | — | US | disclosed |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108614-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | CTSA 221/4885NPC1 2375/4885RAB9A 1580/4885 |
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | CTSA 1159/4885NPC1 73/4885RAB9A 2306/4885 |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | CTSA 1159/4885NPC1 73/4885RAB9A 2306/4885 |
| US-20120046305-A1 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS | TRPA1, TRPV1, TRPV3 | CTSA 1437/4885NPC1 283/4885RAB9A 2725/4885 |
| US-20130165427-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | CTSA 221/4885NPC1 2375/4885RAB9A 1580/4885 |
| US-20130059869-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | CTSA 1159/4885NPC1 73/4885RAB9A 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.